Specific Biologics Announces US$35 Million Series A Financing
Specific Biologics announced a US$35 million Series A financing to advance its gene-editing therapy for ALS. The financing was led by Hatteras Venture Partners.
Related stories
Ottawa Takes Stake in Cohere as AI Firm Opens $4.9 Billion Funding Round
Ottawa took a stake in Cohere as the AI company opened a $4.9 billion funding round.
M impact | EQUITY | Nov 02, 2026, 04:05 PM UTC
Cloud Software Group launches $2 billion senior secured notes offering
The company says proceeds will fund a tender offer. The notes are due 2034.
M impact | EQUITY | Nov 02, 2026, 04:03 PM UTC
South Africa’s New-Energy Vehicle Sales Top 2025 Total in Nine Months
Naamsa said new-energy vehicle sales in South Africa during the first nine months of this year exceeded the total for 2025. In September, one in every nine vehicles sold was a new
L impact | EQUITY | Nov 02, 2026, 04:03 PM UTC
Tower Semiconductor Reports Record Q3 2026 Revenue of $526 Million
Third-quarter revenue rose 33% year over year to a record $526 million. Operating profit was a record $127 million and net profit excluding non-recurring items was a record $120 mi
M impact | EQUITY | Nov 02, 2026, 04:03 PM UTC
GP Petroleums Appoints Arjun Verma Managing Director
GP Petroleums reported second-quarter profit of Rs 15.3 crore.
M impact | EQUITY | Nov 02, 2026, 04:02 PM UTC
ServiceNow Reports Q3 Revenue of $4.106 Billion and Announces Armis Acquisition
ServiceNow reported Q3 2026 revenue of $4.106 billion, up 20.5% year over year, including subscription revenue of $3.988 billion. It also announced a $7.75 billion acquisition of A
M impact | EQUITY | Nov 02, 2026, 04:02 PM UTC